This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Natera, Inc. (NTRA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Natera, Inc. (NTRA).
OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 8.47% and 0.63%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -4.08% and 6.58%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects
by Zacks Equity Research
PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.
Natera (NTRA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -6.52% and -2.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
by Zacks Equity Research
Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
by Zacks Equity Research
Obalon (OBLN) is expected to register robust U.S. revenues in Q3, backed by higher reorders from existing accounts and new order bookings.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of -5.77% and 3.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens focus on driving innovation, ramping up production and expanding geographies.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.
Can The Uptrend Continue for Natera (NTRA)?
by Zacks Equity Research
Natera, Inc. (NTRA) has been on the move lately as the stock has climbed in the past four weeks
Natera (NTRA) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Natera (NTRA) shares rose more than 6% in the last trading session, amid huge volumes.
QIAGEN Ties Up With Natera, Boosts GeneReader NGS Platform
by Zacks Equity Research
QIAGEN (QGEN) forges ahead with deals to strengthen the GeneReader NGS Platform.